GSK (NYSE:GSK) and PDS Biotechnology (NASDAQ:PDSB) Critical Contrast

GSK (NYSE:GSK) and PDS Biotechnology (NASDAQ:PDSB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Institutional and Insider Ownership

15.7% of GSK shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares GSK and PDS Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GSK	17.47%	46.75%	11.53%
PDS Biotechnology	N/A	-208.95%	-83.27%

Analyst Recommendations

This is a summary of recent ratings for GSK and PDS Biotechnology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3	7	1	0	1.82
PDS Biotechnology	1	0	2	0	2.33

GSK currently has a consensus price target of $44.13, indicating a potential downside of 16.71%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 1,536.07%. Given PDS Biotechnology’s stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than GSK.

Risk and Volatility

GSK has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Valuation and Earnings

This table compares GSK and PDS Biotechnology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07 billion	2.50	$7.54 billion	$3.70	14.32
PDS Biotechnology	N/A	N/A	-$37.61 million	($0.82)	-0.67

GSK has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Summary

GSK beats PDS Biotechnology on 8 of the 13 factors compared between the two stocks.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.